Long-Term Vitiligo Data Appear To Lay Opzelura Safety Concerns To Rest

Incyte’s topical JAK inhibitor carries a class-wide severe safety warning and cautions against chronic use, but 52-week results could ease the way for the potential vitiligo indication.